American Academy of Neurology (AAN) 2023 Annual Meeting
Boston, Massachusetts, US 22 April 2023 - 27 April 2023
Conventional vs shorter ocrelizumab infusions: which way to go?
In the ENSEMBLE PLUS study, there appears to be no difference in terms of the frequency and severity of infusion-related reactions (IRRs) between the conventional and shorter infusions of ocrelizumab for the treatment of early relapsing-remitting multiple sclerosis (RRMS). However, patients gravitated towards the shorter regimen more than the conventional method.
Fixed-dose combo tackles PD symptoms while minimizing daytime sleepiness
P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.
Donanemab BLAZEs through Alzheimer’s treatment TRAIL in first active comparator trial
The first study to directly compare two disease-modifying agents for Alzheimer’s disease (AD), the phase III TRAILBLAZER-ALZ 4 study shows promising efficacy and safety data on donanemab vs aducanumab for the treatment of early symptomatic AD.
